BMYBristol-Myers SquibbRunning, no new patients
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
Melanoma
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2/3
- Patients
- 714 (final count)
- Started
- Apr 11, 2018
- Main results expected
- Jan 25, 2021
- Fully finished
- Dec 15, 2030
- Results posted
- Mar 29, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression Free Survival (PFS)
Measured over: From randomization to date of first documented tumor progression or death (up to approximately 33 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03470922 · record last updated 2025-09-09 · checked 2026-11-09 15:42 UTC